Physician profile
Mark E Collins
NPI 1508894882
$2,584.48
in general payments reported to CMS, 2019-2025
27 companies · $81.56 in 2025
The $81.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,840 · 2020: $117 · 2021: $293 · 2022: $12.69 · 2023: $151 · 2024: $89.57 · 2025: $81.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.20 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $441.46 | 2019-2023 | |
| Novo Nordisk INC | $300.04 | 2019-2021 | |
| Glaxosmithkline, LLC. | $207.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $187.11 | 2019 | |
| Lilly USA, LLC | $167.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.68 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Pfizer INC. | $126.56 | 2019 | |
| Merck Sharp & Dohme LLC | $116.04 | 2019 | |
| Amgen INC. | $101.50 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $91.86 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $85.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.13 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $76.20 | 2019 | |
| Abbott Laboratories | $67.21 | 2019-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $64.31 | 2021-2025 | Watchman Flx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.16 | 2019 | |
| Exact Sciences Corporation | $45.37 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $43.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.76 | 2019 | |
| Vivus LLC | $24.94 | 2019 | |
| Allergan, INC. | $23.46 | 2019 | |
| Shire North American Group INC | $19.43 | 2019 | |
| Mannkind Corporation | $19.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.02 | 2025 | Zoryve |
| Ferring Pharmaceuticals INC. | $14.79 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.